These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 31002948)

  • 21. Disulfiram/copper selectively eradicates AML leukemia stem cells in vitro and in vivo by simultaneous induction of ROS-JNK and inhibition of NF-κB and Nrf2.
    Xu B; Wang S; Li R; Chen K; He L; Deng M; Kannappan V; Zha J; Dong H; Wang W
    Cell Death Dis; 2017 May; 8(5):e2797. PubMed ID: 28518151
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD34
    Zeijlemaker W; Grob T; Meijer R; Hanekamp D; Kelder A; Carbaat-Ham JC; Oussoren-Brockhoff YJM; Snel AN; Veldhuizen D; Scholten WJ; Maertens J; Breems DA; Pabst T; Manz MG; van der Velden VHJ; Slomp J; Preijers F; Cloos J; van de Loosdrecht AA; Löwenberg B; Valk PJM; Jongen-Lavrencic M; Ossenkoppele GJ; Schuurhuis GJ
    Leukemia; 2019 May; 33(5):1102-1112. PubMed ID: 30542144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The rarity of ALDH(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients.
    Hoang VT; Buss EC; Wang W; Hoffmann I; Raffel S; Zepeda-Moreno A; Baran N; Wuchter P; Eckstein V; Trumpp A; Jauch A; Ho AD; Lutz C
    Int J Cancer; 2015 Aug; 137(3):525-36. PubMed ID: 25545165
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lower phosphorylation of p38 MAPK blocks the oxidative stress-induced senescence in myeloid leukemic CD34(+)CD38 (-) cells.
    Xiao Y; Zou P; Wang J; Song H; Zou J; Liu L
    J Huazhong Univ Sci Technolog Med Sci; 2012 Jun; 32(3):328-333. PubMed ID: 22684553
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission.
    van Rhenen A; Moshaver B; Kelder A; Feller N; Nieuwint AW; Zweegman S; Ossenkoppele GJ; Schuurhuis GJ
    Leukemia; 2007 Aug; 21(8):1700-7. PubMed ID: 17525725
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Live kinase B1 maintains CD34
    Wang H; Wang X; Xin N; Qi L; Liao A; Yang W; Liu Z; Zhao C
    Mol Cell Biochem; 2017 Oct; 434(1-2):25-32. PubMed ID: 28397012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunophenotypic Detection of Measurable Residual (Stem Cell) Disease Using LAIP Approach in Acute Myeloid Leukemia.
    Zeijlemaker W; Kelder A; Cloos J; Schuurhuis GJ
    Curr Protoc Cytom; 2019 Dec; 91(1):e66. PubMed ID: 31763792
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of a leukemia-initiating stem cell in human mast cell leukemia.
    Eisenwort G; Sadovnik I; Schwaab J; Jawhar M; Keller A; Stefanzl G; Berger D; Blatt K; Hoermann G; Bilban M; Willmann M; Winding C; Sperr WR; Arock M; Rülicke T; Reiter A; Valent P
    Leukemia; 2019 Nov; 33(11):2673-2684. PubMed ID: 30953030
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD34+CD38-CD123+ Cells Are Present in Virtually All Acute Myeloid Leukaemia Blasts: A Promising Single Unique Phenotype for Minimal Residual Disease Detection.
    Al-Mawali A; Pinto AD; Al-Zadjali S
    Acta Haematol; 2017; 138(3):175-181. PubMed ID: 29065396
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A CD38-directed, single-chain T-cell engager targets leukemia stem cells through IFN-γ-induced CD38 expression.
    Murtadha M; Park M; Zhu Y; Caserta E; Napolitano O; Tandoh T; Moloudizargari M; Pozhitkov A; Singer M; Dona AA; Vahed H; Gonzalez A; Ly K; Ouyang C; Sanchez JF; Nigam L; Duplan A; Chowdhury A; Ghoda L; Li L; Zhang B; Krishnan A; Marcucci G; Williams JC; Pichiorri F
    Blood; 2024 Apr; 143(16):1599-1615. PubMed ID: 38394668
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Flow cytometric analysis of CD34
    Mizuta S; Iwasaki M; Bandai N; Yoshida S; Watanabe A; Takashima H; Ueshimo T; Bandai K; Fujiwara K; Hiranuma N; Koba Y; Kawata T; Tamekane A; Watanabe M
    Cytometry B Clin Cytom; 2024 Jan; 106(1):35-44. PubMed ID: 37933409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acquired expression of osteopontin selectively promotes enrichment of leukemia stem cells through AKT/mTOR/PTEN/β-catenin pathways in AML cells.
    Mohammadi S; Ghaffari SH; Shaiegan M; Zarif MN; Nikbakht M; Akbari Birgani S; Alimoghadam K; Ghavamzadeh A
    Life Sci; 2016 May; 152():190-8. PubMed ID: 27063991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification and separation of normal hematopoietic stem cells and leukemia stem cells from patients with acute myeloid leukemia.
    Hoang VT; Hoffmann I; Borowski K; Zepeda-Moreno A; Ran D; Buss EC; Wuchter P; Eckstein V; Ho AD
    Methods Mol Biol; 2013; 1035():217-30. PubMed ID: 23959995
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34-positive AML.
    Daga S; Rosenberger A; Quehenberger F; Krisper N; Prietl B; Reinisch A; Zebisch A; Sill H; Wölfler A
    Cancer Med; 2019 Apr; 8(4):1771-1778. PubMed ID: 30848055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential antigen expression and aberrant signaling via PI3/AKT, MAP/ERK, JAK/STAT, and Wnt/β catenin pathways in Lin-/CD38-/CD34+ cells in acute myeloid leukemia.
    Garg S; Shanmukhaiah C; Marathe S; Mishra P; Babu Rao V; Ghosh K; Madkaikar M
    Eur J Haematol; 2016 Mar; 96(3):309-17. PubMed ID: 26010294
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD34⁺/CD38⁻ acute myelogenous leukemia cells aberrantly express CD82 which regulates adhesion and survival of leukemia stem cells.
    Nishioka C; Ikezoe T; Furihata M; Yang J; Serada S; Naka T; Nobumoto A; Kataoka S; Tsuda M; Udaka K; Yokoyama A
    Int J Cancer; 2013 May; 132(9):2006-19. PubMed ID: 23055153
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FISH+CD34+CD38- cells detected in newly diagnosed acute myeloid leukemia patients can predict the clinical outcome.
    Wang L; Gao L; Xu S; Gong S; Chen L; Lü S; Chen J; Qiu H; Xu X; Ni X; Song X; Zhang W; Yang J; Liu M; Hu X; Wang J
    J Hematol Oncol; 2013 Nov; 6(1):85. PubMed ID: 24517186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of leukemia stem cells in acute myeloid leukemia and their clinical relevance.
    Hoang VT; Zepeda-Moreno A; Ho AD
    Biotechnol J; 2012 Jun; 7(6):779-88. PubMed ID: 22588704
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin.
    Herrmann H; Cerny-Reiterer S; Gleixner KV; Blatt K; Herndlhofer S; Rabitsch W; Jäger E; Mitterbauer-Hohendanner G; Streubel B; Selzer E; Schwarzinger I; Sperr WR; Valent P
    Haematologica; 2012 Feb; 97(2):219-26. PubMed ID: 21993666
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytogenetically aberrant cells in the stem cell compartment (CD34+lin-) in acute myeloid leukemia.
    Mehrotra B; George TI; Kavanau K; Avet-Loiseau H; Moore D; Willman CL; Slovak ML; Atwater S; Head DR; Pallavicini MG
    Blood; 1995 Aug; 86(3):1139-47. PubMed ID: 7542497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.